Patents Assigned to Sulzer Biologics, Inc.
-
Patent number: 6514514Abstract: Disclosed is a cartilage repair product that induces both cell ingrowth into a bioresorbable material and cell differentiation into cartilage tissue. Such a product is useful for regenerating and/or repairing both vascular and avascular cartilage lesions, particularly articular cartilage lesions, and even more particularly mensical tissue lesions, including tears as well as segmental defects. Also disclosed is a method of regenerating and repairing cartilage lesions using such a product.Type: GrantFiled: February 16, 1999Date of Patent: February 4, 2003Assignee: Sùlzer Biologics Inc.Inventors: Brent Atkinson, James J. Benedict
-
Patent number: 6511958Abstract: Disclosed is a cartilage repair product that induces both cell ingrowth into a bioresorbable material and cell differentiation into cartilage tissue. Such a product is useful for regenerating and/or repairing both vascular and avascular cartilage lesions, particularly articular cartilage lesions, and even more particularly mensical tissue lesions, including tears as well as segmental defects. Also disclosed is a method of regenerating and repairing cartilage lesions using such a product.Type: GrantFiled: February 16, 2000Date of Patent: January 28, 2003Assignee: Sulzer Biologics, Inc.Inventors: Brent Atkinson, James J. Benedict
-
Patent number: 6492327Abstract: A method for purifying bone-derived TGF-&bgr; proteins including an anion exchange process, a cation exchange process, and a reverse phase HPLC process, and optionally, a filtration process, a Heparin-Sepharose process, and/or a reverse phase HPLC desalting process. The filtration process preferably selects proteins having a nominal molecular weight between approximately 10 kilodaltons and approximately 100 kilodaltons. Preferably, the anion exchange process uses a strongly cationic resin having quaternary amine functional groups. Preferably, the cation exchange process uses a strongly anionic resin having sulfonic acid functional groups. The TGF-&bgr; proteins can be eluted from the reverse phase HPLC column with an acetonitrile solution in combination with aqueous trifluoracetic acid. The purification processes yield highly enriched TGF-&bgr;1 and TGF-&bgr;2 proteins.Type: GrantFiled: December 19, 2000Date of Patent: December 10, 2002Assignee: Sulzer Biologics Inc.Inventors: Louis Junker, Michael Lewis, Robert Nelson
-
Publication number: 20020026235Abstract: An improved prosthetic graft for the bypass, replacement or repair of vessels and organs that are in contact with blood flow is disclosed. The prosthetic graft includes a porous prosthetic implant and adherent cells adhered to the outer surface of the implant. The adherent cells are transfected with at least one recombinant nucleic acid molecule encoding at least one protein that enhances patency of the graft. The prosthetic graft has a long-term patency and success rate that is superior to other previously described prosthetic grafts designed for such use. Also disclosed are methods of making and using such a graft.Type: ApplicationFiled: October 15, 2001Publication date: February 28, 2002Applicant: Sulzer Biologics, Inc.Inventors: Diane Lee Anderson, John Paul Ranieri, Maurizio Capogrossi Colognesi, Marci Scoccianti, Antonio Facchiano
-
Patent number: 6328762Abstract: An improved prosthetic graft for the bypass, replacement or repair of vessels and organs that are in contact with blood flow is disclosed. The prosthetic graft includes a porous prosthetic implant and adherent cells adhered to the outer surface of the implant. The adherent cells are transfected with at least one recombinant nucleic acid molecule encoding at least one protein that enhances patency of the graft. The prosthetic graft has a long-term patency and success rate that is superior to other previously described prosthetic grafts designed for such use. Also disclosed are methods of making and using such a graft.Type: GrantFiled: April 27, 1999Date of Patent: December 11, 2001Assignee: Sulzer Biologics, Inc.Inventors: Diane Lee Anderson, John Paul Ranieri, Maurizio Capogrossi Colognesi, Marco Scoccianti, Antonio Facchiano
-
Patent number: 6211157Abstract: An angiogenic factor comprising a mixture of proteins derived from bone. The angiogenic protein mixture is produced by a series of steps that allow the proteins to be kept in solution. The angiogenic mixture of bone proteins is produced by a multi-step process that includes at least one ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step.Type: GrantFiled: October 16, 1998Date of Patent: April 3, 2001Assignee: Sulzer Biologics, Inc.Inventors: James J. Benedict, John P. Ranieri, Marsha L. Whitney